InVivo Biosystems is one of the pioneers in precision genetic manipulation providing unparalleled precision with Mos1-mediated Single Copy Insertion (mosSCI). Our groundbreaking techniques enable the precise insertion of transgenes into specific locations within the Caenorhabditis elegans genome. Harnessing the power of the Mos1 transposase, we induce a targeted double-strand break in genomic DNA, seamlessly repaired by utilizing the target plasmid as a template.
More C. elegans Models Services
Advanced Technology Platform
Our service utilizes cutting-edge technology for C. elegans MosSCI transgenesis. We employ state-of-the-art techniques to ensure efficient and precise transgene integration.
Experienced Team of Experts
Our service is supported by a team of highly skilled and knowledgeable experts with extensive experience in C. elegans research and transgenesis methodologies.
Comprehensive Technical Traceability
We provide a whole-process technical trace service, ensuring transparency and accountability. Detailed documentation and records are maintained throughout the transgenesis process for reference and quality assurance.
Short Turnaround Time
We understand the importance of time efficiency and offer a shorter turnaround time for our services.
We have developed a systematic platform for transgenesis in Caenorhabditis elegans using the MosSCI method, and the workflow is shown below.
Select Mos1 Alleles and Verify the presence of Mos1 transposase
Plasmid Construction of transgene expression.
Plasmid Microinjection
Screening for transgenic animals
Confirmation of transgene integration
Delivering the C. elegans model and validation report
The MosSCI service enables you to integrate your desired sequence as a single copy insertion at a designated locus in the C. elegans genome. This is advantageous as it allows you to leave the native gene unmodified. With the MosSCI service you can:
Service Package
Price
Est. Delivery Time
Full Build
$4,635
8 weeks and up
Candidate Lines
$2,785
6 weeks and up
Custom Injection Mix
$1,620
4 weeks and up
Ready to get started?
Ready to connect with us to learn more about working with our company or our technology?
Submit your inquiry below & we will get back to you soon.
The InVivo Biosystems Newsletter is delivered to your inbox bi-weekly,
giving you all of the latest company updates, industry news, and more.
Built on a robust portfolio of CRISPR genome editing patents, InVivo Biosystems has established a comprehensive preclinical discovery and development platform. By leveraging alternative models and proprietary methods, we accelerate go-to-market timelines for pharmaceutical companies and beyond.
